STOCK TITAN
  1. Home
  2. Sec-filings
  3. NNOX
  4. [Form 3] Nano-X Imaging Ltd. Initial Statement of Beneficial Ownership

Nano-X Imaging (NNOX) director Suesskind reports RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
3

Rhea-AI Filing Summary

Nano-X Imaging Ltd. director Dan S. Suesskind has filed a Form 3, disclosing his initial equity holdings in the company. The filing lists ordinary shares underlying restricted share units (RSUs) and several stock option grants, but does not report any new buy or sell transactions.

The director reports 17,544 ordinary shares underlying RSUs granted on December 10, 2024, vesting in twelve equal quarterly installments through December 10, 2027. He also reports 7,792 ordinary shares underlying RSUs granted on December 10, 2025, vesting quarterly through December 10, 2028.

In addition, Suesskind holds stock options over 10,000 ordinary shares at an exercise price of $11.52 per share that are fully vested, plus options over 50,000 shares at $17.63 per share and 12,505 shares at $64.61 per share, which vest in equal quarterly installments until they become fully exercisable on future four-year anniversaries of their respective board approval dates.

Positive

  • None.

Negative

  • None.
Insider Suesskind Dan S
Role null
Type Security Shares Price Value
holding Stock Option (right to buy ordinary shares) -- -- --
holding Stock Option (right to buy ordinary shares) -- -- --
holding Stock Option (right to buy ordinary shares) -- -- --
holding Ordinary shares -- -- --
holding Ordinary shares -- -- --
Holdings After Transaction: Stock Option (right to buy ordinary shares) — 12,505 shares (Direct, null); Ordinary shares — 7,792 shares (Direct, null)
Footnotes (1)
  1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., May 16, 2022), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (May 16, 2026). The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
RSU underlying shares 2024 grant 17,544 ordinary shares Underlying RSUs granted December 10, 2024; vest quarterly to December 10, 2027
RSU underlying shares 2025 grant 7,792 ordinary shares Underlying RSUs granted December 10, 2025; vest quarterly to December 10, 2028
Option position at $11.52 10,000 shares at $11.52/share Stock options fully vested and exercisable; expiration December 31, 2033
Option position at $17.63 50,000 shares at $17.63/share Vests in 16 equal installments; fully exercisable on May 16, 2026
Option position at $64.61 12,505 shares at $64.61/share Vests in 16 equal installments; fully exercisable on August 14, 2027
restricted share units ("RSUs") financial
"The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on December 10, 2024"
Stock Option (right to buy ordinary shares) financial
"security_title": "Stock Option (right to buy ordinary shares)""
vest and settle for underlying shares financial
"RSUs ... vest and settle for underlying shares in twelve equal quarterly installments"
fully vested and exercisable financial
"The options reported in this row were granted ... and are fully vested and exercisable as of the date of this report."
three-year anniversary of the grant date financial
"such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued"
Understanding Insider Trading Forms →
SEC Form 3
FORM 3UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0104
Estimated average burden
hours per response:0.5
1. Name and Address of Reporting Person*
Suesskind Dan S
(Last)(First)(Middle)
C/O NANO-X IMAGING LTD., OFER TECH PARK
94 SHLOMO SHMELTZER ROAD
(Street)
PETACH TIKVA4970602
(City)(State)(Zip)
ISRAEL
(Country)		2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026		3. Issuer Name and Ticker or Trading Symbol
Nano-X Imaging Ltd. [ NNOX ]
3a. Foreign Trading Symbol
5. If Amendment, Date of Original Filed (Month/Day/Year)
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary shares(1)7,792D
Ordinary shares(2)17,544D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year)3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy ordinary shares) (3)02/09/2031Ordinary shares12,505$64.61D
Stock Option (right to buy ordinary shares) (4)12/28/2032Ordinary shares50,000$17.63D
Stock Option (right to buy ordinary shares) (5)12/31/2033Ordinary shares10,000$11.52D
Explanation of Responses:
1. The ordinary shares reported in this row consist of shares underlying restricted share units ("RSUs") that were granted to the Reporting Person on December 10, 2024 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2027) all underlying shares will be issued to the Reporting Person.
2. The ordinary shares reported in this row consist of shares underlying RSUs that were granted to the Reporting Person on December 10, 2025 and that vest and settle for underlying shares in twelve equal quarterly installments (each for 8.33% of the RSUs granted) such that by the three-year anniversary of the grant date (December 10, 2028) all underlying shares will be issued to the Reporting Person.
3. The options reported in this row were granted to the Reporting Person by the Issuer on February 9, 2021 and are fully vested and exercisable as of the date of this report.
4. The options reported in this row were granted to the Reporting Person by the Issuer on December 28, 2022 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., May 16, 2022), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (May 16, 2026).
5. The options reported in this row were granted to the Reporting Person by the Issuer on December 31, 2023 and vest and become exercisable in 16 equal installments of 6.25% each on each three-month anniversary of the date of approval of the grant by the Issuer's Board of Directors (i.e., August 14, 2023), such that all options reported in this row will be exercisable on the four-year anniversary of that grant approval date (August 14, 2027).
Remarks:
Exhibit 24.1 Power of Attorney
/s/ Marina Gofman Feler, attorney-in-fact04/30/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

Source: View Original Filing on SEC EDGAR